We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+16.74%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$13.2M
Cap. Flow
+$2.79M
Cap. Flow %
1.48%
Top 10 Hldgs %
41.3%
Holding
80
New
19
Increased
18
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$7.94M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$7.37M
3
LNTH icon
Lantheus
LNTH
+$6.99M
4
NTRA icon
Natera
NTRA
+$5.75M
5
CMPS
Compass Pathways
CMPS
+$5.64M

Top Sells

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$11.4M
2
AZN icon
AstraZeneca
AZN
+$7.06M
3
PRTA icon
Prothena Corp
PRTA
+$7.06M
4
SYRE icon
Spyre Therapeutics
SYRE
+$3.42M
5
LLY icon
Eli Lilly
LLY
+$3.41M

Sector Composition

Rank Sector Weight
1 Healthcare 94.21%
2 Real Estate 0.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRDX
26
DELISTED
Surmodics
SRDX
$3.01M 1.59%
77,283
+33,305
+76% +$1.46M
MSON
27
DELISTED
Misonix Inc
MSON
$2.94M 1.56%
250,253
+53,952
+27% +$701K
ITMR
28
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$2.87M 1.52%
140,524
– –
AXNX
29
DELISTED
Axonics, Inc. Common Stock
AXNX
$2.76M 1.46%
54,089
+5,289
+11% +$221K
MRK icon
30
Merck
MRK
$317B
$2.21M 1.17%
+27,855
New +$2.18M
ZYXI
31
DELISTED
Zynex
ZYXI
$2.06M 1.09%
129,852
-64,343
-33% -$1.09M
BPMC
32
DELISTED
Blueprint Medicines
BPMC
$1.9M 1.01%
+20,454
New +$1.58M
PRVB
33
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$1.79M 0.95%
139,418
+79,518
+133% +$1M
TARA icon
34
Protara Therapeutics
TARA
$230M
$1.68M 0.89%
+100,000
New +$2.32M
NVRO
35
DELISTED
NEVRO CORP.
NVRO
$1.66M 0.88%
11,926
-6,874
-37% -$918K
RFL icon
36
Rafael Holdings
RFL
$105M
$1.62M 0.86%
106,203
– –
TRIL
37
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.6M 0.85%
+112,742
New +$1.12M
AXGN icon
38
Axogen
AXGN
$2.38B
$1.57M 0.83%
135,111
+54,761
+68% +$636K
LYRA
39
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.24M 0.66%
2,213
+1,000
+82% +$622K
LRMR icon
40
Larimar Therapeutics
LRMR
$436M
$1.16M 0.61%
76,184
+45,014
+144% +$570K
RVNC
41
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.05M 0.55%
41,617
+13,148
+46% +$345K
PVLA
42
Palvella Therapeutics
PVLA
$2.23B
$1.03M 0.55%
+6,250
New +$1.42M
MDNA
43
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$1.03M 0.55%
+248,860
New +$1M
IONS icon
44
Ionis Pharmaceuticals
IONS
$9.06B
$932K 0.49%
19,648
-16,752
-46% -$931K
STAA icon
45
STAAR Surgical
STAA
$1.15B
$868K 0.46%
15,346
-5,082
-25% -$274K
PODD icon
46
Insulet
PODD
$9.65B
$859K 0.46%
3,632
-368
-9% -$77.5K
CRSP icon
47
CRISPR Therapeutics
CRSP
$4.99B
$853K 0.45%
10,200
-7,000
-41% -$621K
ARNA
48
DELISTED
Arena Pharmaceuticals Inc
ARNA
$821K 0.44%
+10,977
New +$732K
KDMN
49
DELISTED
Kadmon Holdings, Inc.
KDMN
$787K 0.42%
200,841
– –
DVAX
50
DELISTED
Dynavax Technologies
DVAX
$725K 0.38%
167,798
+67,798
+68% +$484K
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Soleus Capital Management held 80 positions worth $189M, up 7.5% from $175M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Soleus Capital Management's Q3 2020 filing shows 19 new, 18 increased, 20 reduced and 17 closed positions. Its largest new stake was Mersana Therapeutics: 15,722 shares worth $7.32M. The largest sale was Zymeworks, an estimated $11.4M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 89% a quarter earlier, followed by Real Estate.

  • Soleus Capital Management's largest Q3 2020 buy was Mersana Therapeutics: 15,722 shares worth $7.32M.
  • Soleus Capital Management added most to OraSure Technologies in Q3 2020, an estimated $5.49M increase.
  • Soleus Capital Management's biggest Q3 2020 reduction was Zymeworks, cutting an estimated $11.4M.
  • Soleus Capital Management fully exited Prothena Corp in Q3 2020, selling an estimated $7.06M.
  • Soleus Capital Management's ten largest holdings make up 41% of its $189M portfolio in Q3 2020.
  • Soleus Capital Management opened 19 new positions and closed 17 in Q3 2020.
  • Soleus Capital Management's portfolio value rose 7.5% quarter-over-quarter to $189M.

Based on Soleus Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.